# US 2008/0076814 A1 · Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076814 A1
- Document ID: US20080076814A1
- Status: Published application
- Kind: A1
- Application number: 11/688,589
- Filed: 2007-03-20
- Published: 2008-03-27
- Earliest claimed: 2006-09-22
- Assignees: Janssen Pharmaceutica NV
- Inventors: Mingde Xia; Fina Liotta; Huajun Lu; Meng Pan; Michael P. Wachter; Mark J. Macielag
- Web page: https://patentgrep.com/patent/US20080076814A1

## CPC

- C07D 231/54: condensed with carbocyclic rings or ring systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/18: Feminine contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

## Claims

### Claim 1

A compound having a structure according to formula (I):
or a salt, isomer, prodrug, metabolite or polymorph thereof wherein
the dashed lines between positions 2-3 and positions 3a-9a in formula (I) represent locations for each of two double bonds present when X1R1 is present;
the dashed lines between positions 3-3a and positions 9a-1 in formula (I) represent locations for each of two double bonds present when X2R2 is present;
the dashed line between position 9 and X4R4 in formula (I) represents the location for a double bond;
X1 is absent or lower alkylene;
X2 is absent or lower alkylene;
wherein only one of X1R1 and X2R2 are present;
X3 is absent, lower alkylene, lower alkylidene or —NH—;
when the dashed line between position 9 and X4R4 is absent, X4 is absent or lower alkylene;
when the dashed line between position 9 and X4R4 is present, X4 is absent;
X5 is absent or lower alkylene;
R1 is selected from hydrogen, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), lower alkyl-sulfonyl, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted at one or more positions by halogen, aminosulfonyl, lower alkyl-aminosulfonyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), hydroxy or alkoxy (optionally substituted at one or more positions by halogen or hydroxy);
R2 is selected from hydrogen, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), lower alkyl-sulfonyl, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted at one or more positions by halogen, aminosulfonyl, lower alkyl-aminosulfonyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), hydroxy or alkoxy (optionally substituted at one or more positions by halogen or hydroxy);
R3 is —C(O)-Z1(R6), —SO2—NR7-Z2(R8) or —C(O)—NR9-Z3(R10);
when the dashed line between position 9 and X4R4 is absent, X4 is absent or lower alkylene and R4 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted at one or more positions by hydroxy, oxo, lower alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), lower alkoxy (optionally substituted at one or more positions by halogen or hydroxy) or halogen;
when the dashed line between position 9 and X4R4 is present, X4 is absent and R is CH-aryl or CH-heterocyclyl, wherein aryl or heterocyclyl are each optionally substituted at one or more positions by hydroxy, oxo, lower alkyl, lower alkoxy or halogen;
R5 is absent, hydroxy, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl;
R6 is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl;
R7 is hydrogen or lower alkyl;
R8 is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl;
R9 is hydrogen or lower alkyl;
R10 is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aminosulfonyl, lower alkyl-aminosulfonyl, aryl, aryloxy, arylalkoxy or heterocyclyl;
Z1 and Z2 are each absent or alkyl; and,
Z3 is absent, —NH—, —SO2— or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy).

### Claim 2 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein X1 is absent or lower alkylene; and, R1 is selected from hydrogen, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted at one or more positions by halogen, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), hydroxy or alkoxy (optionally substituted at one or more positions by halogen or hydroxy).

### Claim 3 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein X1 is absent; and, R1 is selected from aryl or C3-C12 cycloalkyl, wherein aryl is optionally substituted at one or more positions by halogen.

### Claim 4 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)-X1(R6), —SO2—NH-Z2(R8) or —C(O)—NH-Z3(R10).

### Claim 5 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)-Z1(R6); X3 is absent, lower alkylene, lower alkylidene or —NH—; Z1 is absent or alkyl; and, R6 is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl are each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl.

### Claim 6 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)-Z1(R6); X3 is absent; Z1 is absent; and, R6 is heterocyclyl.

### Claim 7 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NR9-Z3(R10); X3 is absent, lower alkylene, lower alkylidene or —NH—; R9 is hydrogen or lower alkyl; Z3 is absent, —NH—, —SO2— or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy); and, R10 is aryl, C3-C12 cycloalkyl or heterocyclyl each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aminosulfonyl, lower alkyl-aminosulfonyl, aryl, aryloxy, arylalkoxy or heterocyclyl.

### Claim 8 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent, —NH— or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy); and, R10 is aryl, C3-C12 cycloalkyl or heterocyclyl each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy, carboxy, carbonylalkoxy, aryl or heterocyclyl.

### Claim 9 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent or alkyl; and, R10 is C3-C12 cycloalkyl optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy, carboxy, carbonylalkoxy, aryl or heterocyclyl.

### Claim 10 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent or alkyl; and, R10 is C3-C12 cycloalkyl optionally substituted by one or more alkyl or carbonylalkoxy.

### Claim 11 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent, —NH— or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy); and, R10 is aryl optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), alkoxy, carboxy, carbonylalkoxy, aryl or heterocyclyl.

### Claim 12 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent, —NH— or alkyl; and, R10 is aryl optionally substituted by one or more halogen.

### Claim 13 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein R3 is —C(O)—NH-Z3(R10); X3 is absent; Z3 is absent or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy); and, R10 is heterocyclyl optionally substituted by one or more alkyl.

### Claim 14 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein the dashed line between position 9 and X4R4 is absent; X4 is absent; and, R4 is hydrogen.

### Claim 15 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein the dashed line between position 9 and X4R4 is present, X4 is absent and R4 is CH-aryl optionally substituted on aryl at one or more positions by halogen.

### Claim 16 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof, wherein X5 is absent and R5 is absent.

### Claim 17

A compound of formula (Ia):
or a salt, isomer, prodrug, metabolite or polymorph thereof wherein X1 is absent; X3 is absent; when the dashed line between position 9 and X4R4 is absent, X4 is absent and R4 is hydrogen; when the dashed line between position 9 and X4R4 is present, X4 is absent and R4 is CH-aryl, wherein aryl is optionally substituted at one or more positions by halogen; R1 is selected from aryl or C3-C12 cycloalkyl, wherein aryl is optionally substituted at one or more positions by halogen; R3 is —C(O)-Z1(R6) or —C(O)—NH-Z3(R10); R6 is heterocyclyl; Rio is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl or C3-C12 cycloalkyl are each optionally substituted by one or more halogen, alkyl or carbonylalkoxy; Z1 is absent; and, Z3 is absent, —NH— or alkyl.

### Claim 18 (depends on 1)

The compound of claim 1 or a salt, isomer, prodrug, metabolite or polymorph thereof selected from:
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide,
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide,
1-cyclopentyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide,
2-[(1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carbonyl)-amino]-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester,
1-cyclopentyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1-adamantan-1-yl-ethyl)-amide,
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1-adamantan-1-yl-ethyl)-amide,
1-cyclopentyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide,
1-cyclobutyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide,
1-cyclobutyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide,
1-cyclobutyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1-adamantan-1-yl-ethyl)-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid N′-(2,4-dichloro-phenyl)-hydrazide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-pyridin-2-yl- ethyl]-amide,
(9E)-[1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]piperidin-1-yl-methanone,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid piperidin-1-ylamide,
(2E)-[9-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]-ethenesulfonic acid [(1S)-1-(4-methoxy-phenyl)-ethyl]-amide,
(2E)-[9-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]-ethenesulfonic acid [(1S)-1-phenyl-ethyl]-amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-methoxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-methoxy-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]-amide, or
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide.

### Claim 19 (depends on 18)

The compound of claim 18 selected from:
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide,
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide,
1-cyclopentyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide,
2-[(1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carbonyl)-amino]-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester,
1-cyclopentyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1-adamantan-1-yl-ethyl)-amide,
1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (1-adamantan-1-yl-ethyl)-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid N′-(2,4-dichloro-phenyl)-hydrazide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-pyridin-2-yl- ethyl]amide,
(9E)-[1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]piperidin-1-yl-methanone,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]amide,
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide, or
(9E)-1-(2,4-dichloro-phenyl)-9-(4-fluoro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid piperidin-1-ylamide.
(2E)-[9-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]-ethenesulfonic acid [(1S)-1-(4-methoxy-phenyl)-ethyl]-amide,
(2E)-[9-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazol-3-yl]-ethenesulfonic acid [(1S)-1-phenyl-ethyl]-amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]amide,
(9S*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-methoxy-1-phenyl-ethyl]-amide,
(9R*)-(3-chloro-benzyl)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-methoxy-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide,
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]-amide, or
(9E)-(3-chloro-benzylidene)-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid [(1R)-2-hydroxy-1-phenyl-ethyl]-amide.

### Claim 20 (depends on 1)

A method for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of claim 1.

### Claim 21 (depends on 1, 20)

The method of claim 20 wherein the cannabinoid receptor is a CB1 or CB2 receptor; and, the compound of claim 1 is an agonist, antagonist or inverse-agonist of the receptor.

### Claim 22 (depends on 20)

The method of claim 20 wherein the compound is a CB1 receptor inverse-agonist.

### Claim 23 (depends on 20)

The method of claim 20 wherein the compound is a CB2 receptor agonist.

### Claim 24 (depends on 20)

The method of claim 20 wherein the syndrome, disorder or disease is related to appetite, metabolism, diabetes, glaucoma-associated intraocular pressure, social and mood disorders, seizures, substance abuse, learning, cognition or memory, organ contraction or muscle spasm, bowel disorders, respiratory disorders, locomotor activity or movement disorders, immune and inflammation disorders, unregulated cell growth, pain management or neuroprotection.

### Claim 25 (depends on 24)

The method of claim 24 wherein bowel related syndromes, disorders, or diseases associated with inflammation, with or without pain, are selected from inflammatory bowel disease, disordered bowel motility associated with inflammation arising from surgery, traumatic injury or any sequelae resulting from traumatic injury, intraperitoneal inflammation, basal pneumonia, myocardial infarction, metabolic disturbances or any combination thereof.

### Claim 26 (depends on 25)

The method of claim 25 wherein inflammatory bowel diseases are selected from ulcerative colitis, Crohn's disease or celiac disease.

### Claim 27 (depends on 25)

The method of claim 25 wherein surgery is selected from abdominal surgery, transplantation surgery, bowel resection, orthopedic surgery, cardiovascular surgery or gynecological surgery.

### Claim 28 (depends on 25)

The method of claim 25 wherein traumatic injury is selected from falls, car accident or personal assault.

### Claim 29 (depends on 25)

The method of claim 25 wherein sequelae resulting from traumatic injury are selected from limb fractures, rib fractures, fractures of the spine, thoracic lesions, ischemia or retroperitoneal hecatomb.

### Claim 30 (depends on 25)

The method of claim 25 wherein intraperitoneal inflammation is selected from intraabdominal sepsis, acute appendicitis, cholecystitis, pancreatitis or ureteric colic.

### Claim 31 (depends on 1, 20)

The method of claim 20 wherein the effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 300 mg/kg/day.

### Claim 32 (depends on 20)

The method of claim 20 wherein the syndrome, disorder or disease is a CB1 receptor inverse-agonist mediated appetite related, obesity related or metabolism related syndrome, disorder or disease.

### Claim 33 (depends on 20)

The method of claim 20 wherein the syndrome, disorder or disease is a CB2 receptor agonist mediated bowel related syndrome, disorder, or disease associated with inflammation, with or without pain, selected from inflammatory bowel disease, disordered bowel motility associated with inflammation arising from surgery, traumatic injury or any sequelae resulting from traumatic injury, intraperitoneal inflammation, basal pneumonia, myocardial infarction, metabolic disturbances or any combination thereof.

### Claim 34 (depends on 1, 20)

The method of claim 20 further comprising the step of administering to the subject a combination product and/or therapy comprising an effective amount of a compound of claim 1 and a therapeutic agent.

### Claim 35 (depends on 34)

The method of claim 34 wherein the therapeutic agent is an anticonvulsant or a contraceptive agent.

### Claim 36 (depends on 35)

The method of claim 35 wherein the anticonvulsant is topiramate, analogs of topiramate, carbamazepine, valproic acid, lamotrigine, gabapentin, phenytoin and the like and mixtures or pharmaceutically acceptable salts thereof.

### Claim 37 (depends on 35)

The method of claim 35 wherein the contraceptive agent is a progestin-only contraceptive, a contraceptive having a progestin component and an estrogen component, or an oral contraceptive optionally having a folic acid component.

### Claim 38 (depends on 1)

A method of contraception in a subject comprising the step of administering to the subject a composition, wherein the composition comprises a contraceptive and a CB1 receptor inverse-agonist or antagonist compound of claim 1, wherein the composition reduces the urge to smoke in the subject and/or assists the subject in losing weight.

### Claim 39 (depends on 1)

Use of the compound of claim 1 in the manufacture of a medicament for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

### Claim 40 (depends on 39)

The use of claim 39 wherein the syndrome, disorder or disease is a CB1 receptor inverse-agonist mediated appetite related, obesity related or metabolism related syndrome, disorder or disease.

### Claim 41 (depends on 39)

The use of claim 39 wherein the syndrome, disorder or disease is a CB2 receptor agonist mediated bowel related syndrome, disorder, or disease associated with inflammation, with or without pain, selected from inflammatory bowel disease, disordered bowel motility associated with inflammation arising from surgery, traumatic injury or any sequelae resulting from traumatic injury, intraperitoneal inflammation, basal pneumonia, myocardial infarction, metabolic disturbances or any combination thereof.
